Clinical Trial Update: First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 first-in-human trial update reports on the safety and tolerability of MP0317 in patients with relapsed/refractory advanced solid tumors; the study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• MP0317

Snippet

Sponsor: Molecular Partners AG | Conditions: Advanced Malignant Solid Tumor | Phase 1 | Status: TERMINATED